Chinook Therapeutics
Discovering and Developing Precision Medicines for Rare Kidney Diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $3.5b | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 6142 % | (88 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (6443 %) | (144 %) | (2741 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (9870 %) | (199 %) | (3066 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 4359 % | 188 % | 2304 % |
Source: Company filings or news article
Related Content
Chinook Therapeutics, now a part of Novartis, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of precision medicines for rare and severe chronic kidney diseases. The company operates in the biopharmaceutical market, focusing on innovative treatments for conditions that often lead to dialysis, transplantation, and significant healthcare costs. Chinook's business model revolves around advancing its drug candidates through clinical trials, obtaining regulatory approvals, and ultimately bringing these therapies to market. Revenue is generated through the commercialization of these precision medicines, targeting a niche but critical segment of the healthcare industry. The company serves patients suffering from chronic kidney diseases, healthcare providers, and the broader medical community. Chinook leverages its deep understanding of disease biology, novel translational platforms, and patient stratification tools to develop its therapies. The acquisition by Novartis is expected to bolster its research capabilities and accelerate the development of its drug pipeline.
Keywords: precision medicines, chronic kidney diseases, biopharmaceutical, clinical trials, drug development, patient stratification, translational platforms, healthcare costs, Novartis, renal diseases.